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Summary 
We performed this meta-analysis to update the clinical evidences on 
the relation between clopidogrel non-responsiveness and clinical out-
comes in patients with coronary artery disease (CAD) who underwent 
percutaneous coronary intervention. An electronic literature search 
through MEDLINE, EMBASE, Web of Science, and the Cochrane Library 
and bibliographies of retrieved articles up to January, 2009 was con-
ducted. Studies were included if they had a cohort prospective design, 
if they analysed clopidogrel responsiveness in CAD patients in relation 
to death and/or occurrence of adverse coronary events during follow-
up, and if they reported an adequate statistical analysis. Fourteen 
studies, totalling 4,564 CAD patients followed for a time ranging from 
14 days to one year, were included. The cumulative analysis reported 
that residual platelet reactivity despite clopidogrel treatment was sig-
nificantly associated with an increased risk of death and/or thrombotic 
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recurrences (odds ratio [OR] 5.67, 95% confidence interval [CI] 2.97 to 
10.84; p<0.00001). However, four studies contributed to a consistent 
heterogeneity of the model and evidenced a significant risk of pub-
lication bias, so were excluded from the analysis. This exclusion, how-
ever, did not influence the overall result, by confirming the increased 
risk of cardiovascular recurrences for patients with a poor response to 
clopidogrel treatment (OR 3.58, 95%CI 2.54 to 5.05; p<0.00001). The 
present updated meta-analysis documents a significant association be-
tween residual platelet reactivity under clopidogrel treatment and re-
current cardiovascular events, so suggesting the relevance of ongoing 
interventional studies aimed at tailoring the antithrombotic therapy in 
CAD patients. 
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Introduction 
Large clinical trials have shown that clopidogrel significantly re-
duces the risk of recurrent cardiovascular events in patients with 
coronary artery disease (CAD) (1–5). Indeed, the standard care of 
patients with acute coronary syndromes who underwent percut-
aneous coronary intervention (PCI) is, to date, the dual therapy 
with aspirin and clopidogrel, that has been reported to signifi-
cantly decrease the occurrence of death, myocardial infarction, and 
stroke compared with the use of aspirin alone (1–5). Nevertheless, 
a wide individual variability in response to antiplatelet medi-
cations has been recently reported (6). Furthermore, an increasing 
amount of data on the relation between non-responsiveness to 
antiplatelet therapy and clinical recurrences has been reported (7, 
8). Residual platelet reactivity despite aspirin treatment has been 
showed to be associated with an increased risk of coronary recur-
rences (7). Likewise, studies reporting a similar association with 
clopidogrel non-responsiveness have been published (9–22). Re-
cently, Snoep et al. systematically reviewed the studies investigating 
the association between clopidogrel non-responsiveness and clini-
cal outcome, by evidencing an increased risk of clinical recurrences 
for those with residual platelet reactivity under clopidogrel treat-
ment (8). However, some relevant studies on this issue from then 
to date have been published (19–22). Therefore, we aimed this 
study to update the clinical evidences on the relation between 
clopidogrel non-responsiveness and clinical outcomes in patients 
with CAD who underwent PCI.  
Methods 
We carried out an electronic search of MEDLINE (from 1966 to Ja-
nuary 2009), EMBASE (from 1974 to January 2009), Science Ci-
tation Index (from 1994 to January 2009), and the Cochrane Cen-
tral Register of Controlled Trials to seek for studies that investi-
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gated the possible association between poor response to clopido-
grel therapy and clinical events. The search was performed using a 
combined text word and MeSH search strategy of the terms. Rel-
evant keywords relating to clopidogrel therapy (“clopidogrel” or 
“plavix” or “iscover”) were used in combination with words relat-
ing to responsiveness to the therapy (“resistance” or “resistant” or 
“failure” or “nonrespon*” or “non-respon*” or “low respon*” or 
“low-respon*”) and to the clinical consequences (“clinical con-
sequences” or “clinical consequence” or “cardiovascular events” or 
“adverse events” or “recurrences” or “major adverse cardiac events” 
or “stent thrombosis” or “prognosis” or “outcome”). We used no 
language restrictions. Furthermore, we identified original articles 
by back-referencing from reviews, and relevant studies. We as-
sessed the relevance of studies by using a hierarchical approach 
based on title, abstract, and the full manuscript. 
Inclusion criteria 
We included studies that met the following criteria: (a) cohort 
prospective design, in which clinical outcomes in “non-responder” 
patients were compared with outcomes in “responder” patients; 
(b) patients were receiving clopidogrel therapy at the time of the 
index event; (c) patients were classified prospectively as clopido-
grel “non-responders” or “responders” before the ascertainment of 
any clinical outcome; (d) definition of non-responsiveness to 
clopidogrel was clearly reported; (e) a measure of prospective clini-
cal outcome was used in both groups of patients; (f) relative risk, 
hazard ratio, or odds ratio (OR) and their corresponding 95% con-
fidence intervals (CI) (or data to calculate them) were reported.  
Outcome measures 
Outcomes of interest for the current meta-analysis were major ad-
verse cardiac events (MACE), defined as any cardiovascular event 
(fatal and non-fatal myocardial infarction, stroke, unstable angi-
na), death from cardiovascular causes, ischaemic recurrences 
(symptoms compatible with recurrent ischaemia needing new 
hospitalisation and coronarography), stent thrombosis occurred 
in CAD patients under antiplatelet therapy during follow-up. 
Data collection 
All data were independently extracted by two investigators (F.S., 
and R.M.) through the use of a standardised data extraction tool 
and entered into separate databases. Results were compared, and 
disagreements were resolved by discussion with a third investigator 
(A.M.G.). The inter-observer agreement for the study selection 
was 0.92. For each contributing study, the following information 
was abstracted: leading author’s name, year of publication, age, 
gender, number of patients, aspirin and clopidogrel dosages, du-
ration of follow-up, time of determination of response to clopido-
grel, methods used to determine the response to the therapy and 
definition of clopidogrel “resistance”, number of patients with 
clinical events according to the quality of response to clopidogrel, 
OR or relative risk (RR) of cardiovascular recurrences and cor-
responding 95% CI, and adjustment for potential confounders.  
Statistical analysis 
We pooled results from the individual studies by using Review 
Manager (RevMan) software for Macintosh (version 5.0) by the 
Cochrane Collaboration, and Statistical Package for Social 
Sciences (SPSS) software for Windows (version 13.0). The κ stat-
istic was used to assess agreement between reviewers for study se-
lection. The results of each study were reported as OR, RR, or di-
chotomous frequency data. When available, we used the results of 
the original studies from multivariable models with the most com-
plete adjustment for potential confounders; the confounding vari-
ables included in this analysis are shown in Table 1. We used a ran-
dom-effects model which accounts for inter-study variation and 
provides a more conservative effect than the fixed model. Thus, we 
calculated random-summary OR with 95% CI, by using inverse-
variance method. The potential sources of heterogeneity were as-
sessed by using the Cochrane’s Q test to assess between-study dif-
ferences and the I2 statistic to quantify the proportion of inconsist-Figure 1: Flow chart of search strategy. 
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Table 1: Characteristics of studies included in the meta-analysis. 
Source, 
year (refer-
ence) 
Time of  
deter-
mination 
Outcome, n Cases /  
re-
sponders 
Cases / 
non- 
responders 
OR  
(95%CI) 
Adjustment 
Muller et al., 
2003 (9) 
4 h after LD Subacute 
stent throm-
bosis (n=2) 
0 / 93 2 / 12 44.5 
(9.99–991.7) 
None 
Matetzky et 
al., 2004 (10) 
6 h after LD MACE (n=8) 1 / 45 7 / 15 38.5 
(4.15–357) 
None 
Gurbel et al., 
2005 (11) 
24 h after 
LD 
MACE (n=38) 23 / 144 15 / 48 2.39 
(1.12–5.09) 
None 
Cuisset et al., 
2006 (12) 
12 h after 
LD 
MACE (n=12) 9 / 23 3 / 83 41.6 
(4.74–364) 
Age, gender, CV 
risk factors, heart 
rate, systolic 
blood pressure, 
treatment, CRP 
and P-selectin 
Cuisset et al., 
2006 (13) 
12 h after 
LD 
MACE  
(300 mg: 
n=18)  
(600 mg: 
n=7) 
6 / 256 
300 mg 
1 / 256 
600 mg 
12 / 36 
300 mg 
6 / 22 
600 mg 
300 mg: 9.93 
(3.19–30.90) 
600 mg: 43.16 
(4.89–381.10) 
Together: 
13.82 
(5.30–36.04) 
Age, gender, CV 
risk factors, tro-
ponin elevation, 
ST-segment 
changes, LVEF, ti-
rofiban use 
Geisler et al., 
2006 (14) 
12 h after 
LD 
MACE (n=29) 23 / 341 6 / 22 3.71 
(1.08–12.69) 
Age, gender, dia-
betes, smoking 
habit, hyperten-
sion, LV dysfunc-
tion, prior ACS 
Hochholzer et 
al., 2006 (15) 
At least 2 h 
after LD 
MACE (n=15) 2 / 401 13 / 401 9.6 (2.1–44.3) Age, smoking 
habit, hyperten-
sion, diabetes, 
non-left anterior 
descending PCI,  
diameter steno-
sis, time from 
clopidogrel load-
ing 
Buonamici et 
al., 2007 (16) 
12–18 h 
after LD 
Stent throm-
bosis (n=25) 
16 / 699 9 / 105 3.08 
(1.32–7.16) 
Age, previous MI, 
AMI, multivessel 
disease, total 
chronic occlusion, 
total stent length, 
LVEF, bifurcation 
lesion 
Patients, n 
(age) 
Gender, n 
105 CAD 
(age: ~ 60) 
75M; 30F 
60 STEMI 
(mean age: 
58) 
48M; 12F 
192 CAD 
(age: ~ 60) 
108M; 84F 
106 ACS 
(mean age: 
64.2) 
82M; 24F 
292 ACS 
(mean age: 
64.2) 
222M; 70F 
363 CAD 
(mean age: 
67.5) 
277M; 86F 
802 CAD 
(age: ~ 65) 
627M; 175F 
804 ACS 
(age: ~ 70) 
602M; 202F 
Aspirin and 
clopidogrel 
doses (mg) 
Aspirin: 100 
Clopidogrel: 
LD 600; MD 75 
Aspirin: LD 
300; MD 200 
Clopidogrel: 
LD 300; MD 75 
Aspirin: LD 
325; MD: 75 
Clopidogrel: 
LD 300 (n=75), 
LD 600 (n=60); 
MD 75 
Aspirin: 160 
Clopidogrel: 
LD 300; MD 75 
Aspirin: 160 
Clopidogrel: 
LD 300 
(n=146), 600 
(n=146); 
MD 75 
Aspirin: 100 
Clopidogrel: 
LD 600; MD 75 
Aspirin: 100 
Clopidogrel: 
LD 600; MD 75 
Aspirin: 325 
Clopidogrel: 
LD 600; MD 75 
F-UP 
14 d 
6 m 
6 m 
1 m 
1 m 
3 m 
1 m 
6 m 
Definition of  
residual pla-
telet activity 
LTA (5, 20 μM 
ADP) <10% re-
duction com-
pared to baseline 
LTA (5 μM ADP) 
1st quartile of re-
ductions com-
pared with base-
line 
LTA (20 μM ADP) 
4th quartile 
(>72%) com-
pared to 1–3  
quartiles 
LTA (10 μM ADP) 
4th quartile 
(>70%) vs. 1–3 
quartiles 
LTA (10 μM ADP) 
>70% 
LTA (20 μM ADP) 
>70% 
LTA (5 μM ADP)  
> median (14%) 
LTA (10 μM ADP) 
≥90th percentile 
of controls (70%)
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ency across the study results. Sensitivity analyses were performed 
in order to determine the source of heterogeneity, according to the 
main characteristics of the study (loading dose of clopidogrel: 300 
– 600 mg; duration of follow-up: <6 months – ≥6 months; method 
used to determine clopidogrel non-responsiveness: LTA – Ver-
ifyNow; adjustment for potential confounders: yes – no). Pub-
lication bias was assessed using a funnel plot of effect size against 
standard error. 
Results 
Database searches yielded 326 references. Exclusion of irrelevant 
references by title evaluation left 109 papers. After abstract evalu-
ation additional 70 references were excluded. Moreover, after a de-
tailed review other 25 articles were excluded because they did not 
fulfil our inclusion criteria. At the end of our review process 14 
studies were included in the final analysis for a total of 4,564 pa-
tients (Fig. 1). Characteristics of the included studies are pres-
ented in Table 1. Five studies included CAD patients (stable an-
gina, chronic CAD) (9, 11, 14, 15, 21) while the remaining com-
Source, 
year (refer-
ence) 
Time of  
deter-
mination 
Outcome, n Cases /  
re-
sponders 
Cases / 
non- 
responders 
OR  
(95%CI) 
Adjustment 
Patti et al.,  
2008 (20) 
8 h and 24 
h after in-
tervention 
MACE (n=15) 7 / 120 8 / 40 6.1 (1.1–18.3) Age, LVEF, glyco-
protein IIb/IIIa,  
statin therapy 
Wang et al., 
2008 (21) 
Baseline 
and 24 h 
after LD 
MACE (n=31) 20 / 321 11 / 65 2.44 
(1.09–5.45) 
Age, gender, 
smoking habit, 
diabetes, prior 
CABG, MI, and 
PCI, renal failure, 
EF<30% 
Marcucci et 
al., 2009 (22) 
24 h after 
LD 
MACE (n=51) 22 / 464 29 / 219 3.6 (1.5–9.1) Age, CV risk fac-
tors, renal failure, 
LVEF <40%, 
multivessel dis-
ease, total stent 
length, bifur-
cation lesions, 
number of lesions 
treated and type 
of stent, GpIIb/
IIIa 
CAD, coronary artery disease; LD, loading dose; MD, maintenance dose; LTA, light-transmission aggregometry; ADP, adenosine diphopshate; STEMI, ST-elevation 
myocardial infarction; MACE, major adverse cardiac events; ACS, acute coronary syndromes; CV, cardiovascular; CRP, C-reactive protein; LVEF, left ventricular ejec-
tion fraction; PCI, percutaneous coronary intervention; MI, myocardial infarction; AMI, acute myocardial infarction; VASP, vasodilator-stimulated phosphoprotein; 
CABG, coronary artery bypass graft. 
Patients, n 
(age) 
Gender, n 
160 ACS 
(mean age: 
66) 
129M; 31F 
386 CAD 
(mean age 
68.8) 
257M; 129F 
683 ACS 
(mean age: 
69) 
517M; 166F 
Aspirin and 
clopidogrel 
doses (mg) 
Aspirin: n.d. 
Clopidogrel: 
LD 600; MD 75 
Aspirin: 300 
Clopidogrel: 
LD 75 
Aspirin: LD 
500; MD: 
100–325 
Clopidogrel: 
LD 600; MD 75 
F-UP 
1 m 
12 m 
12 m 
Definition of  
residual pla-
telet activity 
VerifyNow P2Y12 
4th quartile of 
PRU compared to 
1–3  
quartiles 
LTA (20 μM ADP) 
≤10% of differ-
ence between 
aggregation at 
baseline and 24 h 
after LD 
VerifyNow P2Y12 
4th quartile (PRU 
>258) compared 
to 1–3 quartiles 
Frere et al.,  
2007 (17) 
195 ACS 
(age: ~ 65) 
158M; 37F 
Aspirin: 75 
Clopidogrel: 
LD 600; MD 75 
1 m LTA (10 μM ADP) 
>70% 
18 h after 
LD 
MACE (n=14) 3 / 130 11 / 65 8.62 
(2.31–32.15) 
None 
Blindt et al., 
2007 (18) 
99 ACS 
(age: ~ 65) 
74M; 25F 
Aspirin: 100 
Clopidogrel: 
LD 600 (only in 
case of emerg-
ency PCI; MD 
75 
6 m VASP phosphory-
lation 
>48% 
72–96 h 
after LD 
Stent throm-
bosis (n=9) 
n.d. n.d. 1.16 
(1.01–1.33) 
Acute MI, ADP, 
main lesion 
length, n° of 
stents implanted, 
total stent length, 
maximal stent 
length 
Price et al.,  
2008 (19) 
317 ACS 
(mean age: 
68) 
292M; 84F 
Aspirin: 325 
Clopidogrel: 
LD 600; MD 75 
6 m VerifyNow P2Y12 
PRU >235 
12 h after 
LD 
MACE (n=9) 2 / 209 7 / 108 7.17 
(1.46–35.17) 
None
Table 1: Continued
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prised only acute coronary syndrome patients (10, 12, 13, 16–20, 
22). 
The number of participants ranged from 60 to 804, with a sig-
nificantly higher prevalence of males (n=3,468; 75.9%) than fe-
males (n=1,096) and a follow-up period that ranged from 14 days 
to one year.  
All patients were treated with aspirin with a daily dose that 
ranged from 75 to 325 mg. Four studies included a loading dose of 
clopidogrel of 300 mg (10–13), 11 studies of 600 mg (9, 11, 13, 
14–20, 22), while only one study reported a loading dose of 75 mg 
(21). As for the maintenance dose all the studies included a dose of 
75 mg/day of clopidogrel. 
A variety of assays were used to assess response to clopidogrel 
therapy. These included light transmission aggregometry (LTA) 
with the use of adenosine diphosphate as agonist with different 
concentration in most of them (n=10) (9–17,21), point-of-care 
Figure 2: Overall summary estimates of 
odds ratios and 95% confidence intervals 
(CI) for major adverse cardiac events in 
men and women with and without clopido-
grel non-responsiveness. Squares represent 
the effect size; extended lines, 95% CI; dia-
mond, total effect size 
Figure 3: Sensitivity analyses on basis of 
dose of clopidogrel, duration of follow-up, 
method of diagnosis, adjustment for po-
tential confounders. Squares represent the 
effect size; extended lines, 95% confidence in-
tervals (CI). 
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testing in three studies (19, 20, 22), and vasodilator-stimulated 
phosphoprotein (VASP) in one paper (18).  
Overall, 1,205 out of the 4,564 patients (26.4%) were classified 
as clopidogrel non-responders and the remaining 3,359 (73.6%) as 
clopidogrel responders.  
The OR under a random-effects model for cardiovascular recur-
rences associated with a poor response to clopiodgrel in each study 
and overall is shown in Figure 2. Compared to patients showing an 
optimal response to antiplatelet treatment, patients with persistent 
platelet reactivity despite antiplatelet treatment had a significantly 
higher risk of death and/or ischaemic recurrences (OR 5.67, 95% CI 
2.97 to 10.84; p<0.00001). However, a consistent degree of heteroge-
neity was found among the 14 included studies (I2=86%; 
p<0.00001). All the heterogeneity was explained by studies with 
large RR and low number of patients and by an outlier study, that, by 
itself, greatly contributed (40%) to the heterogeneity of the model (9, 
10, 12, 18). This paper by Blindt et al. is the only study that evaluated 
platelet reactivity through the VASP phosphorylation (18). But ex-
cluding these studies, indeed, the heterogeneity disappeared (I2=0%; 
p=0.5) while the estimate of association only slightly decreased by 
remaining significantly associated with an increased risk of adverse 
clinical cardiac events (OR 3.58, 95% CI 2.54 to 5.05; p<0.00001).  
Sensitivity analyses performed after stratification of the studies 
into the different variables showed statistically significant results, 
demonstrating that characteristics of the studies (loading dose of 
clopidogrel, duration of follow-up, method used to determine 
clopidogrel response, adjustment for potential confounders) did 
not influence the overall results of the meta-analysis (Fig. 3). 
However, it should be noted that a greater estimate of association 
for some characteristics of the studies, such as a lower loading dose 
of clopidogrel (300 mg), a shorter period of follow-up (<6 
months), or a method for determining platelet aggregation (LTA) 
can be detected with respect to their counterparts. 
In conclusion, to evaluate the possible presence of publication 
bias among the included studies we performed a funnel plot of ef-
fect size versus standard error that reported a slightly asymmetrical 
visual examination, which is consistent with the conclusion that 
there were some statistical outliers. We identified these outliers as 
the studies previously observed to be the causes of the heteroge-
neity of the model (9, 10, 12, 18). Therefore, we excluded these 
studies from the analysis and the funnel plot showed no visual 
examination of publication bias (Fig. 4). 
Figure 4: Funnel plot of published studies of clopidogrel non-responsiveness and risk of cardiovascular morbidity. Open squares represent in-
dividual studies; black squares represent outlying studies. 
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Discussion 
The present updated meta-analysis conducted on a total popu-
lation of over than 4,500 CAD patients who underwent a PCI 
showed that persistent platelet reactivity despite clopidogrel treat-
ment confers an increased risk of recurrent adverse cardiovascular 
events. Indeed, patients who were classified as clopidogrel non-re-
sponders were at about a five-fold increased risk of non-fatal and 
fatal cardiovascular recurrences with respect to those classified as 
responders. 
Clinical context 
Clopidogrel, in combination with aspirin, is currently the standard 
of care for patients undergoing PCI. Clinical trials have shown 
that, in high-risk patients, prolonged dual antiplatelet treatment is 
more effective than aspirin alone in preventing MACE (1–6). How-
ever, despite the use of such therapy, a considerable number of pa-
tients continue to have recurrent thrombotic events (9–22). Pre-
vious studies have shown a significant inter-individual variability 
in platelet response to clopidogrel therapy in patients with CAD, as 
measured by ex vivo platelet function assay, with up to 25% of pa-
tients classified as non-responders, and a growing degree of evi-
dence that links the recurrence of adverse cardiac events to a poor 
response to clopidogrel is available (6, 8). Indeed, numerous clini-
cal studies have demonstrated that clopidogrel non-responsive-
ness is associated with higher risk of cardiovascular events, includ-
ing cardiac death and stent thrombosis (9–22). In addition, clopi-
dogrel non-responsiveness has also been associated with a higher 
incidence of periprocedural myocardial damage, thrombotic com-
plications, and long-term ischaemic events in patients undergoing 
PCI (23, 24). 
A systematic review with meta-analysis on this issue has been 
recently published by Snoep et al. by reporting, as we do, that lab-
oratory clopidogrel non-responsiveness is a marker of increased 
risk of adverse cardiovascular outcomes in patients undergoing 
PCI with stenting (8). In the present meta-analysis we have up-
dated the issue by adding some very recent studies that comprised 
a considerable number of patients and by including (where avail-
able) in the cumulative analysis results obtained from a multivari-
able model that kept into account possible confounding factors of 
platelet aggregation. Hence, we have increased the number of the 
studied patients of the overall analysis and we have likely improved 
the quality of the included studies. However, despite strict inclu-
sion criteria and in keeping with the previous meta-analysis we 
have found a statistical heterogeneity among the included studies. 
This finding could be strictly linked to the various methodological 
and clinical differences available among the included studies. To 
date, there is still a degree of uncertainty on how, when, and what 
consider as clopidogrel responders. There is not an accepted defi-
nition, and the timing as well as the methods to be used is not yet 
fully established.  
In order to establish the nature of such heterogeneity we have 
identified four studies as outliers because of the low number of pa-
tients, the very large estimates of association and the possible risk 
of publication bias (9, 10, 12, 18). However, after exclusion of these 
studies a positive association between clopidogrel non-responsive-
ness and an increased risk of clinical recurrences still remained, 
thus confirming the overall result.  
Actually, the mechanisms leading to a poor response to clopido-
grel have not been fully elucidated and are considered to involve 
both acquired and genetic factors. Clopidogrel is a pro-drug, 
requiring biotransformation to an active metabolite by cytoch-
rome P450 enzymes. The genes encoding these enzymes are poly-
morphic, and some studies reported some single nucleotide poly-
morphisms in these cytochromes able to confer reduced enzymatic 
function (25). Very recent studies showed that in patients with 
acute coronary syndromes treated with clopidogrel two different 
variants gene encoding for cytochrome P450 were differently as-
sociated with adverse clinical outcomes (26, 27). Moreover, clinical 
factors such as obesity, insulin resistance, and the nature of the cor-
onary event have been found to contribute to the variability of the 
clopidogrel response (6). Another possible explanation of the re-
sistance to thienopyridines could be the underdosing rather than 
in the inability of the drug to depress platelet function. It has been 
reported, indeed, that platelets of patients who responded poorly 
to clopidogrel were capable of being inhibited by a more potent 
thienopyridine such as prasugrel (6). 
According to this, results from the different sensitivity analyses, 
although consistent with the main result of the meta-analysis, sup-
port the hypothesis that differences in response to clopidogrel 
partly depend on some methodological variables such as dosage, 
period of administration and methods used to determine platelet 
aggregation. Subgroup analyses, indeed, reported a greater risk of 
cardiovascular recurrences for patients treated with a lower load-
ing dose of clopidogrel (300 mg vs. 600 mg), with a lesser period of 
treatment (<6 months vs. >6 months) and in whom platelet aggre-
gation was established by means of a point-of-care versus a labora-
tory method. This is consistent with the findings reported by some 
clinical trials that recently showed a stronger suppression of pla-
telet aggregation, and a reduced incidence of cardiovascular 
What is known about this topic? 
● Patients with coronary artery disease and undergoing percut-
aneous coronary intervention are at a much greater risk of death 
and/or major adverse cardiac events.  
● The standard care of these patients is the dual antiplatelet treat-
ment with aspirin and clopidogrel. 
● A consistent proportion of patients under antiplatelet treatment 
shows a clinical non-responsiveness to the therapy. 
What does this study add? 
● Poor responders to clopidogrel treatment are at increased risk of 
cardiovascular clinical recurrences.
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events, with a dosage of 600 mg of clopidogrel with respect to 300 
mg (28, 29).  
Limitations of study 
Some potential limitations can be detected in the present meta-
analysis. First, despite augmented, the number of studies is 
relatively low, and thus our results have to be interpreted carefully. 
Second, a great heterogeneity across the studies is present by likely 
underestimating the overall results of the meta-analysis. On the 
other hand, we have performed some sensitivity analyses sub-
grouping studies with similar characteristics and we have reported 
some outlying studies within the included papers. These studies 
were those with greater measures of association and lower number 
of patients. After the exclusion, however, the overall result was con-
firmed. Third, publication bias in some of the included studies was 
supposed by means of the funnel plot.  
In conclusion, our updated meta-analysis on clinical consequences 
of clopidogrel non-responsiveness among over than 4,500 patients 
followed for a period ranging from two weeks to one year after a 
PCI indicates that poor responders to clopidogrel are at increased 
risk of cardiovascular clinical recurrences with respect to those 
with a good response to the antiplatelet therapy. 
These results suggest the need for interventional studies aimed 
at tailoring the antithrombotic therapy in coronary heart disease 
patients and need to be confirmed by further large clinical trials 
with standardised laboratory methods and well-defined protocols 
to validate the clinical relevance of such response variability to 
clopidogrel.  
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